MedAdvisor Past Earnings Performance
Past criteria checks 3/6
MedAdvisor has been growing earnings at an average annual rate of 7.5%, while the Healthcare Services industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 45.4% per year. MedAdvisor's return on equity is 1.5%, and it has net margins of 0.6%.
Key information
7.5%
Earnings growth rate
25.6%
EPS growth rate
| Healthcare Services Industry Growth | 42.6% |
| Revenue growth rate | 45.4% |
| Return on equity | 1.5% |
| Net Margin | 0.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
MedAdvisor Limited (ASX:MDR) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 07
Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S
Oct 23Is MedAdvisor (ASX:MDR) Using Too Much Debt?
Jun 26Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S
Apr 24Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?
Mar 20Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?
Dec 15Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?
Apr 20MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt
Jun 29Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now
Nov 09Is MedAdvisor (ASX:MDR) A Risky Investment?
Oct 11Is MedAdvisor (ASX:MDR) Using Too Much Debt?
Mar 08MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain
Feb 10What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?
Jan 18
The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares
Dec 22What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?
Dec 18Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation
Nov 22Revenue & Expenses Breakdown
How MedAdvisor makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 122 | 1 | 15 | 0 |
| 31 Mar 24 | 116 | -4 | 15 | 0 |
| 31 Dec 23 | 109 | -9 | 5 | 0 |
| 30 Sep 23 | 104 | -10 | 4 | 0 |
| 30 Jun 23 | 98 | -11 | 13 | 0 |
| 31 Mar 23 | 96 | -8 | 10 | 0 |
| 31 Dec 22 | 93 | -5 | 7 | 0 |
| 30 Sep 22 | 80 | -11 | 5 | 0 |
| 30 Jun 22 | 68 | -17 | 3 | 0 |
| 31 Mar 22 | 66 | -16 | 3 | 0 |
| 31 Dec 21 | 64 | -14 | 3 | 0 |
| 30 Sep 21 | 52 | -14 | 3 | 0 |
| 30 Jun 21 | 39 | -14 | 3 | 0 |
| 31 Mar 21 | 28 | -13 | 4 | 0 |
| 31 Dec 20 | 18 | -12 | 6 | 0 |
| 30 Sep 20 | 14 | -11 | 6 | 0 |
| 30 Jun 20 | 10 | -10 | 6 | 0 |
| 31 Mar 20 | 9 | -9 | 5 | 0 |
| 31 Dec 19 | 9 | -9 | 4 | 0 |
| 30 Sep 19 | 9 | -8 | 5 | 0 |
| 30 Jun 19 | 8 | -8 | 5 | 0 |
| 31 Mar 19 | 8 | -7 | 5 | 0 |
| 31 Dec 18 | 7 | -7 | 5 | 0 |
| 30 Sep 18 | 7 | -6 | 5 | 0 |
| 30 Jun 18 | 7 | -4 | 4 | 0 |
| 31 Mar 18 | 6 | -4 | 4 | 0 |
| 31 Dec 17 | 6 | -4 | 4 | 0 |
| 30 Sep 17 | 5 | -4 | 4 | 0 |
| 30 Jun 17 | 4 | -3 | 3 | 0 |
| 31 Mar 17 | 3 | -4 | 2 | 0 |
| 31 Dec 16 | 2 | -4 | 2 | 0 |
| 30 Sep 16 | 2 | -4 | 1 | 0 |
| 30 Jun 16 | 1 | -3 | 1 | 0 |
| 31 Mar 16 | 1 | -2 | 1 | 0 |
| 31 Dec 15 | 2 | -1 | 1 | 0 |
| 30 Sep 15 | 2 | -1 | 1 | 0 |
| 30 Jun 15 | 2 | -1 | 0 | 0 |
| 30 Jun 14 | 1 | -1 | 0 | 0 |
Quality Earnings: MDR has high quality earnings.
Growing Profit Margin: MDR became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDR has become profitable over the past 5 years, growing earnings by 7.5% per year.
Accelerating Growth: MDR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MDR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (19%).
Return on Equity
High ROE: MDR's Return on Equity (1.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 13:49 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MedAdvisor Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |